approv two key product bring immin growth potenti
final approv
line treatment
adult mcl ahead schedul think demonstr
brukinsa clean profil clear clinic benefit pave road
us commercialis could help china approv
estim brukinsa sale reach mn
record indic tislelizumab clear review process
expect
nov also expect
compani reveal top-lin result pivot nsclc
estim sale reach
result line expect revenu drop
yoy driven increas sale celgen drug china
drop mileston revenu net loss
yoy due rise rise sg cost
lift tp better visibl
brukinsa tislelizumab market launch rais revenu
mn lift tp appli
valuat method h-share tp
ahead schedul fda approv brukinsa btk
brukinsa zanubrutinib receiv fda acceler approv
line treatment adult mantl cell lymphoma mcl base
phase orr data orr includ cr pr
ahead schedul pdufa feb
demonstr brukinsa clean profil clear clinic benefit
view although mcl rel small
indic account
non-hodgkin lymphoma nhl first-step brukinsa
us commercialis pave road indic expans
waldenstrm macroglobulinemia wm chronic lymphocyt
expect sale team readi
brukinsa immin launch us also think fda approv
mcl cll/sll
expect estim brukinsa sale reach
tislelizumab immin approv horizon record
indic tislelizumab clear review process expect
final approv nov domest drug extens
global clinic data think tislelizumab uniqu posit
expect compani reveal top-lin result pivot
nsclc squamou non-squam estim
sale reach mn
result line expect revenu
drop yoy mn driven yoy increas
sale celgen drug china drop mileston
revenu termin
tislelizumab collabor
celgen revenu product sale reach
number share mn
chg prev ep
estimate pot chg tp
estim net loss yoy
mn due increas increas sg
expens remain cash bn plu potenti
compani routin
oper quarter current quarterli cash burn rate
support
synergist
move forward beigene-amgen deal close expect
 sg expens increas add-on commerci
product pipelin howev
product
commercialis cost dedic pipelin
cap bn think increas would moder
maintain outperform lift tp
better visibl brukinsa tislelizumab market launch
increas revenu mn lift tp
tp base dcf model assum
wacc perpetu growth rate appli valuat
method h-share tp
tp
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
serena shao fei zheng jason liu certifi respect compani secur individu analyz view
express report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
price rate histori inc amgn oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori beigen bgne oq
signifi initi assumpt coverag
price rate histori beigen
signifi initi assumpt coverag
charl martineau pm univers toronto decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european rate base stock total return rel analyst coverag univers consist
compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun latin american asia stock exclud japan australia rate
base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price
rel attract stock total return potenti within analyst coverag univers australian new zealand stock
expect total return calcul includ roll dividend yield outperform rate assign greater
equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may
rang outperform under-perform rate overlap neutral threshold oper
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
